Lisa Coleman

Lisa Coleman supports the National Cancer Institute’s mission by managing critical procurement activities that enable cutting-edge cancer research and translational innovation. While her official title is not specified, her role centers on acquiring advanced diagnostic tools, genomic analysis platforms, and precision medicine technologies essential to NCI’s scientific priorities. She oversees complex contract vehicles that support high-capability laboratories and research infrastructure, ensuring timely access to state-of-the-art scientific capabilities. Her acquisitions typically involve biomedical instrumentation, bioinformatics systems, and clinical trial support services, aligning closely with NCI’s strategic focus on accelerating cancer detection and targeted therapeutics. Her primary contractor relationships are dominated by Roche Diagnostics Corporation, indicating a strong reliance on industry leaders in molecular diagnostics, in vitro assays, and integrated laboratory solutions. This partnership reflects a preference for established, high-reliability vendors capable of delivering scalable, FDA-regulated technologies under stringent quality and compliance standards. Coleman’s contracting patterns suggest a focus on long-term, performance-based agreements that ensure continuity in research support and technical service delivery, with minimal reliance on fragmented or speculative vendor ecosystems. Coleman’s procurement portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This pattern signals a prioritization of technical capability, scientific rigor, and operational scalability over socioeconomic targeting, consistent with the high-stakes, mission-critical nature of NCI’s research infrastructure needs. While small business participation is not formally incentivized in her awards, this does not preclude occasional engagement with qualified small firms when their technical offerings meet exacting scientific requirements. Her industry focus centers on diagnostic and genomic technologies, with procurement activity aligned to NAICS categories including medical laboratory services, scientific research and development, and advanced medical device manufacturing. She consistently sources next-generation sequencing systems, liquid biopsy platforms, AI-driven data analytics tools, and integrated biospecimen management solutions—reflecting deep domain expertise in precision oncology and translational research infrastructure.